In contrast, mutant TRβ exerts a dominant-negative effect over PPARγ [91]; it retains DNA-binding ability, competes for PPRE occupancy, and disrupts transcriptional activation of tumor-suppressive programs [100]. The gene discussed is THRB; the disease is neoplasm.